• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.270 +0.030 (+2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,956,604
Open 1.360
Bid (Size) 1.150 (500)
Ask (Size) 1.190 (100)
Prev. Close 1.240
Today's Range 1.220 - 1.360
52wk Range 0.6434 - 1.865
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MaxCyte Q2 Earnings Call Highlights ↗
Today 21:04 EDT
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year... 
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports Second Quarter 2026 Financial Results
Today 16:05 EDT
From MaxCyte, Inc
Via GlobeNewswire

Performance

YTD
-18.1%
-18.1%
1 Month
-8.0%
-8.0%
3 Month
+24.5%
+24.5%
6 Month
+73.9%
+73.9%
1 Year
N/A
N/A

More News

Read More
News headline image
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback ↗
May 12, 2026
Via Chartmill
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook ↗
March 24, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
November 12, 2025
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
November 05, 2025
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
May 13, 2026
Via Chartmill
News headline image
MaxCyte Q1 Earnings Call Highlights ↗
May 12, 2026
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript ↗
March 24, 2026
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
November 11, 2025
Via Benzinga
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 05, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 08, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 06, 2025
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.270
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 08/12/26 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 133.96M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 134M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap